Inhibikase Therapeutics IKT
NASDAQ IKT
$2.00 +0.07 (+3.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

Inhibikase Therapeutics (IKT) Return on Equity [ROE] (2020 - 2026)

Updated

Inhibikase Therapeutics (IKT) posted Return on Equity [ROE] of -40.78% for Q2 2026, up 12.53 percentage points from -53.31% a year earlier but down 8.35 percentage points from the prior quarter.

Analysis

Inhibikase Therapeutics (IKT) Return on Equity [ROE] (2020 - 2026) Analysis & Trends

For FY2025, Inhibikase Therapeutics' Return on Equity [ROE] came in at -38.82%, up 15.20 percentage points from FY2024.

  • Annual Return on Equity [ROE] shows a four-year change of +22.53 percentage points (FY2021 to FY2025).
  • In prior years, Inhibikase Therapeutics' Return on Equity [ROE] was -54.02% in FY2024 (+71.49 pp), -125.51% in FY2023 (-64.52 pp), -60.99% in FY2022 (+0.37 pp) and -61.35% in FY2021.
  • Quarterly Return on Equity [ROE] has run from a low of -878.83% in Q3 2024 to a high of -24.28% in Q3 2021 over five years.
  • On a year-over-year basis, Return on Equity [ROE] has increased in each of the last seven quarters, with an average year-over-year change of +79.44 percentage points over the last eight quarters.
  • The strongest year-over-year quarter for Return on Equity [ROE] in the past five years was Q3 2025, with a gain of 811.98 percentage points; the weakest was Q3 2024, with a drop of 762.71 percentage points.
  • According to Business Quant data, Return on Equity [ROE] for the three prior quarters was -32.43% (Q1 2026), -42.29% (Q4 2025) and -66.85% (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 25.32%
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 7.21%
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn 84.40%
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn 21.39%
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 83.75%
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -18.38%
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 4.97%
10 Inhibikase Therapeutics 349.14 Mn -236.33 Mn - -40.78%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -40.78%
Mar 31, 2026 -32.43%
Dec 31, 2025 -42.29%
Sep 30, 2025 -66.85%
Jun 30, 2025 -53.31%
Mar 31, 2025 -42.53%
Dec 31, 2024 -60.61%
Sep 30, 2024 -878.83%
Jun 30, 2024 -320.14%
Mar 31, 2024 -227.06%
Dec 31, 2023 -154.56%
Sep 30, 2023 -116.12%
Jun 30, 2023 -88.26%
Mar 31, 2023 -78.52%
Dec 31, 2022 -78.45%
Sep 30, 2022 -68.88%
Jun 30, 2022 -59.18%
Mar 31, 2022 -46.36%
Dec 31, 2021 -36.25%
Sep 30, 2021 -24.28%
API Access

Inhibikase Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=IKT&period=max&api_key=YOUR_API_KEY